Johnson & Johnson

(Reuters) - Johnson & Johnson (N:JNJ) reported a 7.4 percent fall in quarterly sales as the impact of a strong dollar more than offset higher sales of its older drugs such as Invega line of products for schizophrenia and ADHD treatment Concerta. Revenue fell to $17.10 billion in the third quarter from $18.47 billion a year earlier. International sales fell nearly 14 pct to $8.31 billion in the quarter, including a currency impact of 15.8 percent, the company said.